Trial: 202107082

A phase II trial with a safety lead-in to evaluate the addition of APX005M, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma

Phase

II

Principal Investigator

Weiss, Mia

Disease Site

Sarcoma; Soft Tissue

Learn more about this study at: clinicaltrials.gov